CDC Global Services, a wholly-owned subsidiary of CDC Corporation, has signed a binding term sheet to acquire an IT services provider primarily focused on business intelligence solutions for
Novartis has received FDA approval for Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from the company. Extavia is approved by
University of Texas in Houston, in a study, has reported that stereotactic body radiotherapy (SBRT) is a highly effective alternative treatment for some cancer patients with spinal metastases.
Vasogen and IntelliPharmaCeutics (IPC) have entered into a definitive agreement, subject to shareholder and regulatory approvals. As per the deal, Vasogen will combine with IPC under a plan
CSL Behring has announced that Helixate FS, Antihemophilic Factor (Recombinant), has been approved by the FDA. It is for routine prophylaxis in children with hemophilia A who are
Gloucester has reported that it will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC)
Labopharm has commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products against Par Pharmaceutical, relating to Ultram ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are
The Valspar Corporation has reported its results for the third-quarter ended July 31, 2009. The company’s third-quarter sales totaled $794.6m, 17% lower than sales in the third quarter
FDA has approved Protalix BioTherapeutics’ treatment protocol for prGCD, the proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD), for the treatment of Gaucher disease. The treatment protocol allows
GeoPharma has reported a decrease in revenues for the first quarter of FY2010, to $5.2m, compared to $6.4m for the same period of FY2009. Overall Gross Profits from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.